Below is an overview of the different media outlets that have quoted or interviewed ARM experts in their news stories. The placements are organized by year, starting with the most recent.
FDA Takes Major Step to Ease Access to CAR-T Therapy
'Superbabies' Startup Seeks Funds for Controversial Gene Editing Push
FDA's top cell and gene therapy leaders exit agency in ongoing CBER changes
Gene therapy faces fresh uncertainty as two more top FDA officials depart
FDA Takes Major Step to Ease Access to CAR-T Therapy
Over 30 CEOs of European CGT Companies Asked EU to Streamline Regulatory Processes
Scientific societies call for a moratorium on using CRISPR to create genetically modified children
Advocacy groups and experts call for decade-long ban on germline editing
Gene editing leaders call for 10-year suspension of heritable human genome editing
HHS Secretary Favors Regenerative Medicine Over Traditional Pharma: Blessing And Curse?
What The EMA Can Teach HTA Bodies About Joint Clinical Assessments
EU HTA Regulation: ‘Stepping Beyond’ JCAs May Be Needed For Very Rare Disease Drugs
Impatient about cell and gene therapy? Progress in biotech is not always linear
Why Cell & Gene Therapy Companies Should Talk with RFK Jr.
Reuters Events Trailblazing Women in Pharma 2025
Deals, Summit’s bravado and gene therapy headwinds
#JPM25 live blog day 1
Decentralized Manufacturing Sponsors Must ‘Do Their Homework’ To Impress US & EU Regulators
Gene therapy's slow rollout offers a reality check
EU rules threaten to cut new treatments for rare diseases
Meeting on the Mesa to Highlight Cell and Gene Therapy Opportunities, Challenges
Gene Therapy And Accelerated Approval: US FDA Mulls Pooling Data To Shrink Postmarket Studies
Thirty-two organisations say Health Technology Assessment rules risk blocking access to new medicines
Worries Over EU JCAs Push Telethon To Speed Up Gene Therapy Filing Plan
Europe is set to shake up the way it assesses new medicines. Gene therapy makers are worried
Joint Clinical Assessments of ATMPs Add to Ethical Concerns Over Need for Randomized Trial
‘Pivotal’ Regulation On EU Joint Clinical Assessments Extends Dossier Deadlines
Joint Clinical Assessments: EU Guidance On Evidence May Be Flexible For ATMPs And Single Arm Trials
Sickle Cell Patients Face a Tough Choice: Be Cured or Have Kids
Sickle Cell Gene Therapy In Medicaid: CMMI Model As ‘Bandwidth Extender’ For Less Resourced States
FDA's Peter Marks says some secondary cancer cases after CAR-T therapy may be 'causal,' but benefits still
Unanswered questions following reports of secondary malignancies after CAR-T cell therapy
Sign up for ARM’s weekly newsletter on sector news and alerts for events, reports, and other engagement opportunities.
